United States SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 6)*

IONIS PHARMACEUTICALS, INC. (formerly Isis Pharmaceuticals, Inc.)

(Name of Issuer)

	Common Stock	
	(Title of Class of Securities)	
	462222100	
	(CUSIP Number)	
	December 31, 2016	_
	(Date of Event Which Requires Filing This Statement)	
Check the appropriate box to designate	the rule pursuant to which this Schedule is filed:	
☐ Rule 13d-1(b)		
⊠ Rule 13d-1(c)		
☐ Rule 13d-1(d)		

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP	No	46222	22100	
1.	Names of Reporting Persons			
	BB Bio	otech	AG	
2.	Check tl (a) ⊠		propriate Box if a Member of a Group (See Instructions) □	
3.	SEC Use Only			
4.	Citizenship or Place of Organization			
	Switze	rlan	d	
		5.	Sole Voting Power	
Nun	nber of		0	
S	hares	6.	Shared Voting Power	
Ow	eficially ned by		6,913,172	
	Each porting	7.	Sole Dispositive Power	
Person with:			0	
	, 2027	8.	Shared Dispositive Power	
-	1 4		6,913,172	
9.	Aggrega	ite An	nount Beneficially Owned by Each Reporting Person	
10	6,913, 1		Annual Annual De (O) Fold In Control Change T	
10.	Cneck 11	tne F	aggregate Amount in Row (9) Excludes Certain Shares	
11.	Percent	of Cla	ss Represented by amount in Row (9)	
	5.7%			
12.	. Type of Reporting Person (See Instructions)			
	нс,со			

CUSIP	No	46222	22100		
1.	1. Names of Reporting Persons				
	Biotech Target N.V.				
			cation Nos. of above persons (entities only): N/A		
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) □				
3.	SEC Use Only				
4.	Citizens	ship or	Place of Organization		
	Curacao				
		5.	Sole Voting Power		
Number of			0		
Sl	nares	6.	Shared Voting Power		
Beneficially Owned by			6,913,172		
Rep	ach orting	7.	Sole Dispositive Power		
Person			0		
with:		8.	Shared Dispositive Power		
			6,913,172		
9.	Aggregate Amount Beneficially Owned by Each Reporting Person				
	6,913,172				
10.	Check i	f the A	Aggregate Amount in Row (9) Excludes Certain Shares		
11.	Percent of Class Represented by amount in Row (9)				
	5.7%				
12.	Type of Reporting Person (See Instructions)				
	60				

lten	tem 4. Ownership				
	Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.				
	(a)	Amount beneficially owned: 6,913,172			
	(b)	Percent of class: 5.7%			

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote _____0

(ii) Shared power to vote or to direct the vote 6,913,172

(iii) Sole power to dispose or to direct the disposition of ______0

(iv) Shared power to dispose or to direct the disposition of 6,913,172

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. **BB Biotech AG** Date: February 13, 2017 /s/ Michael Hutter Signatory Authority **Michael Hutter** Name: Signatory Authority Title: Date: February 13, 2017 /s/ Ivo Betschart Signatory Authority **Ivo Betschart** Signatory Authority Title: **Biotech Target N.V.** <u>February 13, 2017</u> /s/ Michael Hutter

SIGNATURES

Date: February 13, 2017

/s/ **Ivo Betschart**Signatory Authority

Signatory Authority

Michael Hutter

Signatory Authority

e: **Ivo Betschart**

Title:

Title: Signatory Authority

5 of 6

Exhibit Index

Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.*

^{*}Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.'s Schedule 13G filed with the Securities and Exchange Commission on July 20, 2011.